In immunotherapy‐favored cancers, using ROI‐ST, a study involving 152 non‐small cell lung cancer (NSCLC) patients revealed that the spatially enriched 163+ tumor‐associated macrophages (TAM) in the TME are associated with immunotherapy resistance, driven by the upregulation of CD27, ITGAM, and CCL5 expression within the tumor cavity.190. This evidence concerns the gene ITGAM and neoplasm.